{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T20:33:50Z","timestamp":1786566830934,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["NCKUH-11103032"],"award-info":[{"award-number":["NCKUH-11103032"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["11303061"],"award-info":[{"award-number":["11303061"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jfma.2026.07.029","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:20:03Z","timestamp":1785237603000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of a multilevel hospital intervention on hepatitis screening and risk management in neuroinflammatory patients receiving immune therapy"],"prefix":"10.1016","author":[{"given":"Yi-Ting","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Chun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-616X","authenticated-orcid":false,"given":"Po-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Jy","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2925-5352","authenticated-orcid":false,"given":"Sheng-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2899-1136","authenticated-orcid":false,"given":"Yuan-Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Tsung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2026.07.029_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2026.07.029_bib2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ije\/dyaa253","article-title":"The global burden of chronic hepatitis B virus infection: comparison of country-level prevalence estimates from four research groups","volume":"50","author":"Schmit","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jfma.2026.07.029_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2026.07.029_bib4","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4297","article-title":"Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program","volume":"6","author":"Hu","year":"2018","journal-title":"PeerJ"},{"key":"10.1016\/j.jfma.2026.07.029_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Polaris Observatory","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2026.07.029_bib6","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2026.07.029_bib7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep4.1531","article-title":"Secular trends and geographic maps of hepatitis C virus infection among 4 million blood donors in Taiwan from 1999 to 2017","volume":"4","author":"Chen","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jfma.2026.07.029_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.35772\/ghm.2021.01064","article-title":"Taiwan accelerates its efforts to eliminate hepatitis C","volume":"3","author":"Chien","year":"2021","journal-title":"Glob Health Med"},{"key":"10.1016\/j.jfma.2026.07.029_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458520952311","article-title":"The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement","volume":"27","author":"Moiola","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.jfma.2026.07.029_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-022-00646-5","article-title":"Vaccination and immunotherapies in neuroimmunological diseases","volume":"18","author":"Winkelmann","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jfma.2026.07.029_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1055\/s-0034-1390395","article-title":"A neurologist's guide to safe use of immunomodulatory therapies","volume":"34","author":"Vodopivec","year":"2014","journal-title":"Semin Neurol"},{"key":"10.1016\/j.jfma.2026.07.029_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jfma.2026.07.029_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2026.07.029_bib14","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3748\/wjg.v17.i15.1927","article-title":"An overview of occult hepatitis B virus infection","volume":"17","author":"Said","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jfma.2026.07.029_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12072-008-9065-2","article-title":"Should chronic HBV infected patients with normal ALT treated: debate","volume":"2","author":"Sarin","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2026.07.029_bib16","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3748\/wjg.v19.i14.2256","article-title":"Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels","volume":"19","author":"Sinn","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jfma.2026.07.029_bib17","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2026.07.029_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2026.07.029_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep.27843","article-title":"Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area","volume":"62","author":"Hsu","year":"2015","journal-title":"Hepatology"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626007588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626007588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T20:21:31Z","timestamp":1786566091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626007588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"alternative-id":["S0929664626007588"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.07.029","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of a multilevel hospital intervention on hepatitis screening and risk management in neuroinflammatory patients receiving immune therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}